Full Text View
Tabular View
Study Results
Related Studies
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients
This study has been completed.
Study NCT00255177   Information provided by VGX Pharmaceuticals, LLC

First Received on November 15, 2005.   Last Updated on October 30, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hepatitis C Virus Infection
Additional conditions recognized in this trial
Hepatitis
Hepatitis A
Hepatitis C
Virus Diseases
More general conditions related to this trial
Digestive System Diseases
Enterovirus Infections
Flaviviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Picornaviridae Infections
RNA Virus Infections
Interventions listed in this trial
VGX-410 (Mifepristone)
Placebo
Additional drug interventions recognized in this trial
Mifepristone
More general drug interventions related to this trial
Abortifacient Agents
Abortifacient Agents, Steroidal
Contraceptive Agents
Contraceptive Agents, Female
Contraceptives, Oral
Contraceptives, Oral, Synthetic
Contraceptives, Postcoital
Contraceptives, Postcoital, Synthetic
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Luteolytic Agents
Menstruation-Inducing Agents
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses
Sponsors listed in this trial
VGX Pharmaceuticals, LLC


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services